中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

China Cognition and Aging Study

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态招聘中
赞助商
Capital Medical University
合作者
Beijing Tiantan Hospital
Beijing Chao Yang Hospital
Fu Xing Hospital, Capital Medical University
Peking Union Medical College Hospital
Peking University First Hospital
Peking University Third Hospital
Chinese PLA General Hospital
China-Japan Friendship Hospital
Beijing Geriatric Hospital
The First Affiliated Hospital of Dalian Medical University
Fujian Medical University Union Hospital
Guangzhou Psychiatric Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital of Guangxi Medical University
The Affiliated Hospital Of Guizhou Medical University
Handan Central Hospital
Hebei General Hospital
First Hospital of Shijiazhuang City
Tangshan Worker's Hospital
Hunan Provincial People's Hospital
Kaifeng Central Hospital
People's Hospital of Zhengzhou University
Wuhan University Zhongnan Hospital
First Affiliated Hospital of Harbin Medical University
Tongji Hospital
People's Hospital Affiliated Hubei Medical University
The Third Xiangya Hospital of Central South University
Xiangya Hospital of Central South University
First Hospital of Jilin University
China-Japan Union Hospital, Jilin University
Subei People's Hospital of Jiangsu
Nantong University Affiliated Hospital
Mineral General Hospital, Xuzhou
Jiangxi Provincial People's Hopital
Anshan Central Hospital
The Affiliated Zhongshan Hospital of Dalian University
First Hospital of China Medical University
Baotou Central Hospital
General Hospital of Ningxia Medical University
The People's Hospital of Ningxia
The Affiliated Hospital of Qingdao University
The 88th Hospital of PLA
Qilu Hospital of Shandong University
Qilu Hospital of Shandong University (Qingdao)
Shandong Provincial Hospital
Qingdao Municipal Hospital
The First Affiliated Hospital of Shanxi Medical University
Tang-Du Hospital
First Affiliated Hospital Xi'an Jiaotong University
Ruijin Hospital
RenJi Hospital
Shanghai Changzheng Hospital
Affiliated Hospital of North Sichuan Medical College
Tianjin Huanhu Hospital
Tianjin Medical University General Hospital
Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region
Ningbo Medical Center Lihuili Hospital
First Affiliated Hospital of Wenzhou Medical University
First Affiliated Hospital of Zhejiang University
Shao Yifu Hospital of Zhejiang Medical University
Zhejiang Provincial People’s Hospital
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
The Second Affiliated Hospital of Chongqing Medical University
The First Affiliated Hospital of Anhui Medical University
People's Hospital of Chongqing
Dongfang Hospital Beijing University of Chinese Medicine
Zigong First People's Hospital

关键词

抽象

The Cognition and Aging Study (COAST) was designed to establish a prospective cohort to clarify the clinical and genetic characteristics, pathogenesis, diagnosis, treatment of MCI, AD, and VCI in China to establish a national database, to develop a strategy for prevention of dementia. The overarching goals of the COAST are as follow:
1. To construct a prospective cohort, then to establish database that provide not only comprehensive epidemiological data on the AD and dementia of Chinese elders, but also biological samples and laboratory and image data.
2. To determine the conversion rates from MCI to dementia or AD and risk factors for the progression from MCI to dementia or AD.
3. To identify and validate imaging and blood/CSF biomarkers for the early detection and tracking of AD.
4. To uncover novel risk genes for complex AD and identify the genes related pathogenesis of the disease.

描述

This study involved participants including amnestic mild cognitive impairment (aMCI), sporadic Alzheimer's disease (SAD), familial Alzheimer's disease (FAD), Vascular cognitive impairment (VCI), and APOE gene cohort (cognitive normal subjects). Research contents are as follow:

1. Neuropsychological characteristics of Chinese aMCI, SAD, VCI: analyze the cognitive function, daily living ability and mental behavior symptoms using MMSE, MoCA, etc. during the baseline and follow-up period.

2. Neuroimaging of Chinese aMCI, SAD, and VCI: explore the neuroimaging characteristics and disease evolution characteristics through the apocalyptic atrophy, cortical thickness of structure MRI, and standardized uptake values of functional imaging FDG-PET.

3. Prevention of Chinese aMCI, SAD, and VCI: find the risk factors and environmental factors which were possible related to development of these disease, and propose a preventional strategy for dementia in China.

4. Pathogenesis of Chinese aMCI, SAD, and VCI: test the investigator's findings (risk factors, genetic factors, environmental factors) in this cohort on animal models.

日期

最后验证: 07/31/2019
首次提交: 08/22/2018
提交的预估入学人数: 08/28/2018
首次发布: 08/30/2018
上次提交的更新: 10/27/2019
最近更新发布: 10/29/2019
实际学习开始日期: 01/09/2008
预计主要完成日期: 12/31/2027
预计完成日期: 12/31/2027

状况或疾病

Mild Cognitive Impairment
Alzheimer Disease, Late Onset
Familial Alzheimer Disease (FAD)
Vascular Cognitive Impairment
APOE Gene Cohort (Cognitive Normal Subjects)

-

手臂组

干预/治疗
Amnestic mild cognitive impairment (MCI)
Mild cognitive impairment subjects with memory loss as predominant symptom
Sporadic Alzheimer's disease (SAD)
Mild to moderate sporadic Alzheimer's disease subjects
Familial Alzheimer's disease (FAD)
Familial Alzheimer disease subjects with known or unknown mutations
Vascular cognitive impairment (VCI)
Cognitive impairment subjects caused by cerebral small vessel disease, including vascular cognitive impairment no dementia, vascular dementia, mixes dementia
APOE gene cohort
Cognitive normal subjects with ApoE ε4 positive or negative

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
取样方式Non-Probability Sample
接受健康志愿者
标准

Amnestic mild cognitive impairment (aMCI)

Inclusion Criteria:

1. Diagnosis according to 2004 Peterson's aMCI criteria.

2. Clinical Dementia Rating (CDR) = 0.5.

3. Memory loss is prominent, and may also be with other cognitive domain impairment.

4. Insidious onset, slow progress.

5. Not reaching the level of dementia.

Exclusion Criteria:

1. With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral vascular disease (Fazekas score ≥ 2 points).

2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).

3. Other systemic diseases that can cause cognitive impairment(such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).

4. Mental and neurodevelopmental retardation.

5. Other diseases known to cause cognitive impairment.

6. Contraindications to nuclear magnetics.

7. Suffering from a disease that cannot be combined with cognitive examination.

8. Refuse to draw blood.

9. Refuse to sign the informed consent at baseline

Sporadic Alzheimer's disease (SAD)

Inclusion Criteria:

1. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) or National Institute on Aging and the Alzheimer's Assocation (NIA-AA) criteria.

2. Subjects and their informed persons can complete relevant and follow-up examinations.

3. Subjects or their authorized legal guardians sign the informed consent.

Exclusion Criteria:

1. With a family history of dementia.

2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).

3. Other systemic diseases that can cause cognitive impairment(such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).

4. Mental and neurodevelopmental retardation.

5. Other diseases known to cause cognitive impairment.

6. Contraindications to nuclear magnetics.

7. Suffering from a disease that cannot be combined with cognitive examination.

8. Refuse to draw blood.

9. Refuse to sign the informed consent at baseline

Familial Alzheimer's disease (FAD)

Inclusion Criteria:

1. Written informed consent obtained from participant or legal guardian prior to any study-related procedures.

2. Members who carry mutations or not carry mutations in familial Alzheimer's disease pedigree (familial Alzheimer disease is defined as at least two first- degree relatives).

3. Aged 18 (inclusive) or older.

4. At least two persons who can provide reliable information for the study. Note: Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or National Institute on Aging and the Alzheimer's Assocation (NIA-AA) criteria. A diagnosis of mild cognitive impairment (MCI) is assigned according to Petersen criteria.

Exclusion Criteria:

1. Under age 18.

2. Medical or psychiatric illness that would interfere in completing initial and follow-up visits.

3. No one who can serve as a study informant.

4. With current or past neurological or psychiatric illnesses such as schizophrenia, epilepsy, brain tumors, severe head trauma and other diseases which can induce dementia.

5. With history of alcohol or drug abuse.

Vascular cognitive impairment (VCI)

Inclusion Criteria:

1. Diagnosis according to the criteria for small vessel VCI, with the following three core elements:

1. Cognitive impairment: memory decline can be highlighted

2. Vascular factors

3. Causal relationship between cognitive impairment and vascular factors

2. Cognitive impairment lasts for 3 months or more, and the CDR global score ≥0.5 point.

3. All patients need to meet the following MRI criteria:

1. Multiple (≥3) small infarcts (3-20 mm in diameter) with or without any degree of white matter lesions (WML); or moderate to severe WML (Fazekas score ≥ 2) , with or without small infarction; or ≥ 1 small infarct in key parts of the cortex, such as: caudate nucleus, globus pallidus, thalamus and so on.

2. No WML caused by cortical infarction, watershed infarction, hemorrhage, hydrocephalus, or other causes (such as multiple sclerosis).

3. No hippocampus or entorhinal cortex atrophy, Medial Temporal Lobe Atrophy (MTA)≤ 1 point.

4. Subjects and their informed persons can complete relevant and follow-up examinations.

5. Subjects or their authorized legal guardians sign the informed consent.

Exclusion Criteria:

1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).

2. Other systemic diseases that can cause cognitive impairment(such as liver, renal, and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).

3. Other diseases known to cause cognitive impairment.

4. Hereditary or inflammatory small vessel disease, such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).

5. Contraindications to nuclear magnetics.

6. Refuse to draw blood.

7. Refuse to sign the informed consent at baseline.

APOE gene cohort

Inclusion Criteria:

1. Aged 18 (inclusive) or older.

2. APOE genotyping has to be obtained from all subjects.

3. Normal MMSE and MoCA evaluations. MMSE>19 points for illiteracy, >24 points for those educated less than 7 years, >27 points for those educated equal to or more than 7 years. MoCA>13 points for illiteracy, >19 points for those educated less than 7 years, >24 points for those educated equal to or more than 7 years.

Exclusion Criteria:

1. Subjects with abnormal MMSE or MoCA scores.

2. Subjects with a history of cerebral infarction, traumatic brain injury confirmed by MRI imaging.

3. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).

4. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).

5. Mental and neurodevelopmental retardation.

6. Other diseases known to cause cognitive impairment.

7. Contraindications to nuclear magnetics.

8. Refuse to draw blood.

9. Refuse to sign the informed consent at baseline.

结果

主要结果指标

1. The prevalence of MCI and AD measured using a population-based cross-sectional survey with a multistage cluster sampling design [an average of 2 years]

2. The conversion rate of normal to MCI to AD in Chinese [an average of 2 years]

3. The biomarkers for normal (pre-MCI), MCI and AD diagnosis [an average of 2 years]

Humoral biomarkers are included Aβ42, Aβ40, phosphated tau and total tau in plasma, cerebrospinal fluid, saliva, and urine. Imaging biomarkers are included cerebral volume, glucose metabolism, amyloid and tau deposition of whole brain or hippocampus.

4. The risk factors (genetic and environmental factors) for MCI, AD and VCI at genomic and expression levels [an average of 2 years]

Discover risk factors including genetic susceptibility loci (APOE genes and other risk genes) using gene sequencing, cardiovascular risk factors (blood glucose, cholesterol, homocysteine) using laboratory tests, and unhealthy lifestyle using questionnaire.

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge